Drug Profile


Alternative Names: CB-500,929; DX-88; EPI-KAL2; FOV 2302; Kalbitor

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dyax
  • Developer Cubist Pharmaceuticals; Dyax; Fovea Pharmaceuticals; Neopharm Ltd; Shire
  • Class Analgesics; Anti-inflammatories; Peptides; Recombinant proteins
  • Mechanism of Action Plasma-kallikrein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Suspended Retinal oedema
  • Discontinued Angioedema; Surgical blood loss

Most Recent Events

  • 22 Jan 2016 Dyax has been acquired by and merged into Shire
  • 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co
  • 01 Jun 2014 CMIC terminates its licence for ecallantide in Japan (Dyax 10-K, February 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top